Zafar R S, Zeng Z, Walz D A
Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201.
Arch Biochem Biophys. 1992 Sep;297(2):271-6. doi: 10.1016/0003-9861(92)90672-j.
Thrombospondin is a major glycoprotein of the platelet alpha-granule and is secreted during platelet activation. Several protease-resistant domains of thrombospondin mediate its interactions with components of the extracellular matrix including fibronectin, collagen, heparin, laminin, and fibrinogen. Thrombospondin, as well as fibronectin, is composed of several discretely located biologically active domains. We have characterized the thrombospondin binding domains of plasma fibronectin and determined the binding affinities of the purified domains; fibronectin has at least two binding sites for thrombospondin. Thrombospondin bound specifically to the 29-kDa amino-terminal heparin binding domain of fibronectin as well as to the 31-kDa non-heparin binding domain located within the larger 40-kDa carboxy-terminal fibronectin domain generated by chymotrypsin proteolysis. Platelet thrombospondin interacted with plasma fibronectin in a specific and saturable manner in blot binding as well as solid-phase binding assays. These interactions were independent of divalent cations. Thrombospondin bound to the 29-kDa fibronectin heparin binding domain with a Kd of 1.35 x 10(-9) M. The Kd for the 31-kDa domain of fibronectin was 2.28 x 10(-8) M. The 40-kDa carboxy-terminal fragment bound with a Kd of 1.65 x 10(-8) M. Heparin, which binds to both proteins, inhibited thrombospondin binding to the amino-terminal domain of fibronectin by more than 70%. The heparin effect was less pronounced with the non-heparin binding carboxy-terminal domain of fibronectin. By contrast, the binding affinity of the thrombospondin 150-kDa domain, which itself lacked heparin binding, was not affected by the presence of heparin. Based on these data, we conclude that thrombospondin binds with different affinities to two distinct domains in the fibronectin molecule.
血小板反应蛋白是血小板α颗粒的主要糖蛋白,在血小板活化过程中分泌。血小板反应蛋白的几个抗蛋白酶结构域介导其与细胞外基质成分的相互作用,这些成分包括纤连蛋白、胶原蛋白、肝素、层粘连蛋白和纤维蛋白原。血小板反应蛋白以及纤连蛋白均由几个离散定位的生物活性结构域组成。我们已经对血浆纤连蛋白的血小板反应蛋白结合结构域进行了表征,并测定了纯化结构域的结合亲和力;纤连蛋白至少有两个与血小板反应蛋白的结合位点。血小板反应蛋白特异性结合纤连蛋白的29 kDa氨基末端肝素结合结构域以及由胰凝乳蛋白酶蛋白水解产生的位于较大的40 kDa羧基末端纤连蛋白结构域内的31 kDa非肝素结合结构域。在印迹结合以及固相结合试验中,血小板血小板反应蛋白以特异性和可饱和的方式与血浆纤连蛋白相互作用。这些相互作用不依赖于二价阳离子。血小板反应蛋白以1.35×10⁻⁹ M的解离常数(Kd)结合到29 kDa纤连蛋白肝素结合结构域。纤连蛋白31 kDa结构域的Kd为2.28×10⁻⁸ M。40 kDa羧基末端片段以1.65×10⁻⁸ M的Kd结合。与两种蛋白质都结合的肝素抑制血小板反应蛋白与纤连蛋白氨基末端结构域的结合超过70%。肝素对纤连蛋白非肝素结合羧基末端结构域的作用不太明显。相比之下,本身缺乏肝素结合的血小板反应蛋白150 kDa结构域的结合亲和力不受肝素存在的影响。基于这些数据,我们得出结论,血小板反应蛋白以不同亲和力结合纤连蛋白分子中的两个不同结构域。